明德生物收盘上涨2.48%，滚动市盈率124.04倍，总市值48.13亿元

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Mingde Biological Technology Co., Ltd., particularly its stock performance and valuation metrics [1][2] - As of July 3, the closing price of Mingde Biological was 20.7 yuan, reflecting a 2.48% increase, with a rolling PE ratio of 124.04, marking a new low in 17 days, and a total market capitalization of 4.813 billion yuan [1] - The average PE ratio for the medical device industry is 51.48, with a median of 36.88, positioning Mingde Biological at the 108th rank within the industry [1][2] Group 2 - As of the first quarter of 2025, six institutions held shares in Mingde Biological, including four funds and two insurance companies, with a total holding of 13.8456 million shares valued at 250 million yuan [1] - The main business of Mingde Biological includes the research, production, sales, and service of in vitro diagnostic reagents and instruments, as well as solutions for critical care information and third-party medical testing services [1] - The latest financial report for the first quarter of 2025 shows that the company achieved a revenue of 69.9603 million yuan, a year-on-year increase of 14.76%, while the net profit was -3.662988 million yuan, a year-on-year decrease of 111.43%, with a gross profit margin of 16.37% [1]